Skip to main content

Arrowhead Pharmaceuticals, Inc.

ARWR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000879407

In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.73B in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding Arrowhead Pharmaceuticals, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of ARWR: Q4 2023 compared with Q1 2024
MeasureQ4 2023Of which not filed for Q1 2024Q1 2024Change
Holders2663273+10
Shares77.5M26.9K96.7M+19.2M (+24.8%)
Value$2.37B$822.8K$2.76B+$392.6M (+16.6%)

3 institutions that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (40)

Institutions that held Arrowhead Pharmaceuticals, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to ARWR in Q1 2024
InstitutionSharesValue% of portfolio
T. Rowe Price Investment Management, Inc.1,758,883$50.3M0.03%
Millennium Management LLC326,971$9.35M0.01%
Octagon Capital Advisors LP250,000$7.15M0.87%
Natixis204,000$5.83M0.03%
Susquehanna Fundamental Investments, LLC128,083$3.66M0.17%
Affinity Asset Advisors, LLC120,000$3.43M0.56%
Essex Investment Management Co LLC72,299$2.07M0.41%
ExodusPoint Capital Management, LP68,647$1.96M0.02%
Exome Asset Management LLC55,700$1.59M1.36%
Erste Asset Management GmbH47,000$1.35M0.02%
Ghost Tree Capital, LLC35,000$1.00M0.32%
TD Asset Management Inc28,400$812.2K0.00%
Fox Run Management, L.L.C.28,098$803.6K0.17%
EFG Asset Management (North America) Corp.27,745$792.5K0.14%
NVWM, LLC27,581$788.8K0.22%
Bayesian Capital Management, LP25,303$723.7K0.07%
Mariner, LLC22,199$634.9K0.00%
Resona Asset Management Co.,Ltd.21,162$605.2K0.00%
Franklin Resources Inc20,770$594.0K0.00%
Myecfo, LLC18,497$529.0K0.31%
Scientech Research LLC15,230$435.6K0.23%
Prelude Capital Management, LLC12,700$363.2K0.02%
Cetera Investment Advisers12,370$353.8K0.00%
Gratus Wealth Advisors, LLC12,250$277.0K0.05%
HSBC Holdings PLC9,521$272.3K0.00%
Oxford Asset Management LLP9,520$272.3K0.29%
Virtu Financial LLC9,411$269.0K0.02%
Graham Capital Management, L.P.7,983$228.3K0.01%
Mackenzie Financial Corp7,299$208.8K0.00%
CIBC Private Wealth Group, LLC1,100$31.1K0.00%
Rise Advisors, LLC714$20.4K0.01%
Chilton Capital Management LLC600$17.2K0.00%
Harbour Investments, Inc.350$10.0K0.00%
New Covenant Trust Company, N.A.269$7.69K0.01%
Meeder Asset Management Inc72$2.06K0.00%
Global Assets Advisory, LLC40,242$1.43K0.07%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC48$1.37K0.00%
Umb Bank N A28$8010.00%
Riggs Asset Managment Co. Inc.14$4010.00%
Rothschild Investment LLC10$2860.00%

Sold out (30)

Institutions that held Arrowhead Pharmaceuticals, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.

Not filed for Q1 2024 yet (3)

Institutions that held Arrowhead Pharmaceuticals, Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ARWR in Q4 2023 that haven't filed for Q1 2024
InstitutionShares, Q4 2023Value, Q4 2023
Putnam Investments LLC18,098$553.8K
NinePointTwo Capital7,458$228.0K
Neo Ivy Capital Management1,337$41.0K